Journal of Hematology & Oncology

Article	Citations
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	764
Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma	437
Disruption of the sorcin‒PAX5 protein‒protein interaction induces ferroptosis by promoting the FBXL12-mediated ubiquitination of ALDH1A1 in pancreatic cancer	433
Targeting GPRC5D for multiple myeloma therapy	430
Involvement of inflammasomes in tumor microenvironment and tumor therapies	424
Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML	400
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	385
Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer	333
A novel non-invasive exhaled breath biopsy for the diagnosis and screening of breast cancer	328
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management	327
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial	320
Helicobacter pylori and gastric cancer: mechanisms and new perspectives	311
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting	290
Cancer vaccines: current status and future directions	288
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL	271
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders	263
Gene and cell therapies in China: booming landscape under dual-track regulation	260
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies	255
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma	251
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents	244
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	244
The regulation of insulin receptor/insulin-like growth factor 1 receptor ratio, an important factor for breast cancer prognosis, by TRIP-Br1	230
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA	226
A four-stage model for murine natural killer cell development in vivo	225
Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report	225

Current and future treatment strategies in chronic lymphocytic leukemia	219
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT	208
Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden	203
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena	202
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma	197
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	195
Emerging role of RNA sensors in tumor microenvironment and immunotherapy	180
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	177
Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial	176
Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation	174
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	173
Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer	167
Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia	164
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation	153
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting	152
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients	149
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	148
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	146
In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy	146
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast	146
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients	144
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells	142
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	141
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium	131
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)	126
D-ribose-5-phosphate inactivates YAP and functions as a metabolic checkpoint	125
Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting	124
Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer	124
LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC	124
Correction: A single-cell and spatially resolved atlas of human osteosarcomas	119
Correction: hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype	119
Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study	118
APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential	116
Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	115
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma	113
HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine	112
Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine	111
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin	111
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence	108
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial	108
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia	107
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors	106
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials	106
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma	104
Recent developments in immunotherapy for gastrointestinal tract cancers	103
Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy	102
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation	101
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells	99
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD–positive AML	99
Mesenchymal stem/stromal cells in cancer therapy	98

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leuke	98
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	98
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses	98
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients	97
Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis	97
Integrins regulate stemness in solid tumor: an emerging therapeutic target	96
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms	96
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation	96
Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives	96
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation	95
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma	95
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	93
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies	93
m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer	92
SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing	90
RETRACTED ARTICLE: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA	89
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)	89
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	88
Applications of single-cell sequencing in cancer research: progress and perspectives	88
Metabolic reprogramming in the tumor microenvironment of liver cancer	85
Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021	85
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy	83
Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy	82
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis	82
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	82
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies	82
Personalized nanovaccines for treating solid cancer metastases	81
Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study	80
Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors	79
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma	79
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	79
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis	78
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	76
Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma	75
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain	75
DTX-P7, a peptide–drug conjugate, is highly effective for non-small cell lung cancer	75
Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study	75
Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study	73
Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting	73
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression	72
Correction: Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells	71
Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients	71
Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation	70
Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response	70
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia	70
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia	69
Hemophagocytic lymphohistiocytosis after COVID-19 vaccination	69
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma	65
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers	64
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias	63
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study	61
Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies	61
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase	60
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma	60
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease	60
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study	60
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study	59
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	58
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	58
Mature B, T and NK-cell, plasma cell and histiocytic/dendritic cell neoplasms: classification according to the World Health Organization and International Consensus Classification	58
Correction: A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1	58
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	58
Pharmacological activity of OST-01, a natural product from baccharis coridifolia, on breast cancer cells	57
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	57
Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution	57
Correction: Immunosenescence: a key player in cancer development	57
Landscape of biallelic DNMT3A mutant myeloid neoplasms	56
Mirvetuximab soravtansine: current and future applications	55
Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance	55
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression	54
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties	53
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	52
Integrated proteogenomic characterization of urothelial carcinoma of the bladder	52
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial	51
Consensus, debate, and prospective on pancreatic cancer treatments	51
Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells	50
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial	49
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies	49
Correction: Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma	49
Born to survive: how cancer cells resist CAR T cell therapy	49

Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study	49
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	48
The potential role of N7-methylguanosine (m7G) in cancer	48
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia	48
Targeting neddylation E2s: a novel therapeutic strategy in cancer	47
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant	47
How we treat primary immune thrombocytopenia in adults	47
Payload diversification: a key step in the development of antibody–drug conjugates	47
Long non-coding RNAs in brain tumors: roles and potential as therapeutic targets	46
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation	46
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal	46
Momelotinib: an emerging treatment for myelofibrosis patients with anemia	46
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC	46
Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers	46
Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer	46
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?	45
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis	45
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma	45
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	45
Recent advances in therapeutic strategies for non-small cell lung cancer	45
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	45
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	44
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	44
Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma	44
CAR-T cells and BiTEs in solid tumors: challenges and perspectives	44
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress	44
A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes	43
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel	43
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study	42
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR	41
Targeting MCL-1 in cancer: current status and perspectives	41
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	41
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned	41
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers	41
Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis	40
Critical role of the gut microbiota in immune responses and cancer immunotherapy	40
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	40
Advances in targeting histone deacetylase for treatment of solid tumors	40
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial	40
Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy	39
Ferroptosis: principles and significance in health and disease	39
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling	39
Targeting CD47 for cancer immunotherapy	38
Liquid biopsy: current technology and clinical applications	38
Recent advances in therapeutic strategies for triple-negative breast cancer	38
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy	38
Emerging strategies to target RAS signaling in human cancer therapy	37
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022	37
Retraction Note: HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression	37
Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins	36
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients	36
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia	36
Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer	36
Correction to: Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN	35
Impact of frontline treatment approach on outcomes of myeloid blast phase CML	35
Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation	35
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair	34
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology	34
Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors	34
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status	34
GSK3-beta as a candidate therapeutic target in soft tissue sarcomas	33
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	33
Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma	33
Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference	32
Tumor cell integrin β4 and tumor stroma E-/P-selectin cooperatively regulate tumor growth in vivo	32
Proteomic characterization of esophageal squamous cell carcinoma response to immunotherapy reveals potential therapeutic strategy and predictive biomarkers	32
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	31
Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system	31
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting	31
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lympho	31
SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism	30
Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement	30
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	29
Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions	28
Vaccines: a promising therapy for myelodysplastic syndrome	28
SELP Asp603Asn and severe thrombosis in COVID-19 males	28
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality	28
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia	28
Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears	28
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation	28
PD-1 blockade immunotherapy as a successful rescue treatment for disseminated adenovirus infection after allogeneic hematopoietic stem cell transplantation	27
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers	27
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2	27
Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination	27
A higher CD34 + cell dose correlates with better event-free survival after KIR-ligand mismatched cord blood transplantation for childhood acute myeloid leukemia	27
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies	27
METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma	26
Correction: DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis	26
Correction to: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies	26
Correction: SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing	26
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation	26
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	26
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms	26
Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine	26
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT	26